AURISCO PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 23.35 CNY | -1.44% |
|
-5.92% | -9.57% |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,364 | 8,830 | 10,029 | 10,488 | 9,485 | - | - |
| Enterprise Value (EV) 1 | 6,364 | 8,830 | 10,029 | 10,488 | 9,485 | 9,485 | 9,485 |
| P/E ratio | 37.8 x | 52.4 x | 47.5 x | 36.4 x | 24.2 x | 18.4 x | 15.1 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 8.82 x | 11 x | 9.95 x | 8.31 x | 5.66 x | 4.42 x | 3.82 x |
| EV / Revenue | 8.82 x | 11 x | 9.95 x | 8.31 x | 5.66 x | 4.42 x | 3.82 x |
| EV / EBITDA | - | 37.6 x | 32.6 x | 25.7 x | 18.3 x | 14.3 x | 11.6 x |
| EV / FCF | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - |
| Price to Book | - | 5.86 x | 5.98 x | 5.33 x | 4.09 x | 3.54 x | 2.85 x |
| Nbr of stocks (in thousands) | 401,000 | 401,000 | 406,195 | 406,195 | 406,195 | - | - |
| Reference price 2 | 15.87 | 22.02 | 24.69 | 25.82 | 23.35 | 23.35 | 23.35 |
| Announcement Date | 4/19/21 | 4/29/22 | 4/14/23 | 4/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 721.4 | 803.4 | 1,008 | 1,263 | 1,677 | 2,144 | 2,486 |
| EBITDA 1 | - | 234.9 | 307.8 | 407.4 | 516.9 | 663 | 818.8 |
| EBIT 1 | - | 193.6 | 241.3 | 330.7 | 455.1 | 595.3 | 730.8 |
| Operating Margin | - | 24.1% | 23.93% | 26.2% | 27.14% | 27.76% | 29.4% |
| Earnings before Tax (EBT) 1 | - | 192 | 240.8 | 329.1 | 453.6 | 593.9 | 729.4 |
| Net income 1 | - | 168.7 | 210.9 | 289.4 | 391.6 | 515.3 | 629.4 |
| Net margin | - | 21% | 20.92% | 22.92% | 23.36% | 24.03% | 25.32% |
| EPS 2 | 0.4200 | 0.4200 | 0.5200 | 0.7100 | 0.9667 | 1.270 | 1.550 |
| Free Cash Flow | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 4/19/21 | 4/29/22 | 4/14/23 | 4/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | 11.7% | 13.3% | 16.1% | 16.9% | 19.3% | 18.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | 10.5% | 12.3% | 12.6% |
| Assets 1 | - | - | - | - | 3,730 | 4,189 | 4,995 |
| Book Value Per Share 2 | - | 3.760 | 4.130 | 4.840 | 5.710 | 6.600 | 8.190 |
| Cash Flow per Share 2 | - | 0.5000 | 0.4100 | 0.9500 | 0.7800 | 1.040 | 1.360 |
| Capex 1 | - | 250 | 216 | 305 | 321 | 214 | 327 |
| Capex / Sales | - | 31.12% | 21.39% | 24.15% | 19.16% | 10% | 13.15% |
| Announcement Date | 4/19/21 | 4/29/22 | 4/14/23 | 4/28/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
23.35
CNY
Average target price
31
CNY
Spread / Average Target
+32.76%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -9.57% | 1.31B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- 605116 Stock
- Financials Aurisco Pharmaceutical Co.,Ltd.
